PDL seeks to provide a significant return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. In late 2012, PDL began providing alternative sources of capital through royalty monetizations and debt facilities and in 2016, began making equity investments in commercial stage companies, the first being Noden Pharma DAC. PDL has committed over $1.4 billion and funded approximately $1.1 billion in these investments to date. PDL is headquartered in Incline Village,
For more information, please visit www.pdl.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pdl-biopharma-to-hold-annual-meeting-of-stockholders-on-june-9-2017-300435778.html
News Provided by Acquire Media